SOURCE: Equity News Circuit

Equity News Circuit

May 20, 2013 08:20 ET

Free Research Reports on MERU, RSOL, SCTY and VNDA Issued by the Paragon Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwired - May 20, 2013) - The Paragon Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

Meru Networks, Inc. (NASDAQ: MERU) shares declined 11.22 percent on volume of nearly 500,000 shares traded Friday to close at $3.56 a share. The company reported revenues of $24.7 million for the first quarter of 2013, an increase of 27 percent when compared to revenues of $19.4 million a year ago.

Find out more about Meru Networks including full access to the free equity report at: www.ParagonReport.com/MERU

Real Goods Solar, Inc. (NASDAQ: RSOL) shares soared 129.87 percent on volume of 8.95 million shares traded Friday to close at $4.03 a share. The company recently launched their "PowerOn" kit. "PowerOn makes converting to solar energy easier than ever with pre-packaged, professionally designed residential systems starting at less than $6,000," said Kam Mofid, CEO Real Goods Solar.

Find out more about Real Goods Solar including full access to the free equity report at: www.ParagonReport.com/RSOL

SolarCity Corp. (NASDAQ: SCTY) shares surged 26.09 percent on volume of 7.86 million shares traded Friday to close at $45.00 a share. The company reported its customer base grew 106 percent year-over-year to 57,400. SolarCity deployed 46 MW in the first quarter, an increase of 12 percent when compared to a year ago.

Find out more about SolarCity including full access to the free equity report at: www.ParagonReport.com/SCTY

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) shares jumped 19.64 percent on volume of 3.38 million shares traded to close at $6.58 a share. Lazard Capital has recently raised the company's price target to $17 from $11 and has maintained its "buy" rating on the stock. Shares of Vanda have gained approximately 78 percent year-to-date.

Find out more about Vanda Pharmaceuticals including full access to the free equity report at: www.ParagonReport.com/VNDA

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information